Yellow Fever Outbreaks in Unvaccinated Populations, Brazil, 2008-2009

PLoS Neglected Tropical Diseases

Volumn 8, Issue 3, 2014, Pages

  Romano, Alessandro Pecego Martins ^a,b   Costa, Zouraide Guerra Antunes ^a   Ramos, Daniel Garkauskas ^a   Andrade, Maria Auxiliadora ^b   de Jayme, Valéria Sá ^b   de Almeida, Marco Antônio Barreto ^c   Vettorello, Kátia Campomar ^c   Mascheretti, Melissa ^d   Flannery, Brendan ^e,f  

^a MINISTÉRIO DA SAÚDE   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c Division of Epidemiological Surveillance   (Brazil)

^d Center for Epidemiological Surveillance   (Brazil)

^e PAN AMERICAN HEALTH ORGANIZATION   (Brazil)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; ARTICLE; ASEPTIC MENINGITIS; BRAZIL; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; DIGESTIVE SYSTEM DISEASE; DISEASE CONTROL; DISEASE SURVEILLANCE; ENCEPHALITIS; EPIZOOTIC HEMORRHAGIC DISEASE; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENINGOENCEPHALITIS; MORBIDITY; NEUROLOGIC DISEASE; RISK ASSESSMENT; TREATMENT RESPONSE; VACCINATION; VECTOR CONTROL; YELLOW FEVER;

ADOLESCENT; ADULT; AGED; BRAZIL; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 84897447400     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002740     Document Type: Article

References (41)

1. Monath TP, (2001) Yellow fever: an update. Lancet Infect Dis 1: 11-20.
2. Monath TP, Cetron MS, Teuwen DE (2008) Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines, 5th ed. Philadelphia, PA: Elsevier. pp. 959-1055.
3. World Health Organization (2013) Vaccines and vaccination against yellow fever: WHO Position Paper - June 2013. Weekly Epidemiological Record 88: 269-284.
4. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, et al. (2011) The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 11: 622-632.
5. Soper F, (1936) Jungle yellow fever. A new epidemiological entity in South America. Revista de Hygiene e Saúde Pública 10: 107-144.
6. Pan American Health Organization (2005) Control of Yellow Fever: Field Guide. Washington, D.C.: PAHO. 30 p.
7. Almeida MAB, Santos E, Cardoso JC, Fonseca DF, Noll CA, et al. (2012) Yellow fever outbreak affecting Alouatta populations in southern Brazil (Rio Grande do Sul State), 2008-2009. Am J Primatol 74: 68-76.
8. Ministry of Health (2009) Situação Epidemiológica das Zoonoses de Interesse à Saúde Pública. Boletim Eletrônico Epidemiológico Available at: http://portalsaudegovbr/portal/arquivos/pdf/boletim_epidemiologico_zoonoses_062009pdf. Brasilia, Brazil: Secretaria de Vigilancia em Saude, Ministerio da Saude. pp. 1-4.
9. Vasconcelos PF, (2010) Yellow fever in Brazil: thoughts and hypotheses on the emergence in previously free areas. Rev Saude Publica 44: 1144-1149.
10. Soper F, Smith H, (1938) Vaccination with virus 17D in control of jungle yellow fever in Brazil. Acta Conventus Tertii de Tropicis atque Malariae Morbis. Amsterdam pp. 295.
11. Massad E, Coutinho FA, Burattini MN, Lopez LF, Struchiner CJ, (2005) Yellow fever vaccination: how much is enough? Vaccine 23: 3908-3914.
12. Struchiner CJ, Luz PM, Dourado I, Sato HK, Aguiar SG, et al. (2004) Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 132: 939-946.
13. Romano APM, Ramos DG, Araújo FAA, Siqueira GAM, Ribeiro MPD, et al. (2011) Febre amarela no Brasil: recomendações para a vigilância, prevenção e controle. Epidemiol Serv Saúde 20: 101-106.
14. Soper FL, (1963) The elimination of urban yellow fever in the Americas through the eradication of Aedes aegypti. Am J Public Health Nations Health 53: 7-16.
15. Massad E, Burattini MN, Coutinho FA, Lopez LF, (2003) Dengue and the risk of urban yellow fever reintroduction in Sao Paulo State, Brazil. Rev Saude Publica 37: 477-484.
16. Massad E, Coutinho FA, Burattini MN, Lopez LF, (2001) The risk of yellow fever in a dengue-infested area. Trans R Soc Trop Med Hyg 95: 370-374.
17. World Health Organization (2008) Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol Rec 83: 105.
18. Cardoso JC, Almeida MAB, Santos E, Fonseca DF, Sallum MAM, et al. (2010) Yellow fever virus in Haemagogus leucocelaenus and Aedes serratus mosquitoes, southern Brazil, 2008. Emerg Infect Dis 16: 1918-1924.
19. Carmo E, Martins E, Pelucci H, Maia M, Duzzi R, et al. (2002) Brote de fiebre amarilla selvática en Minas Gerais. Boletín Informativo PAI Organización Pan-Americana de Salud 24: 5-6.
20. de Souza RP, Foster PG, Sallum MA, Coimbra TL, Maeda AY, et al. (2010) Detection of a new yellow fever virus lineage within the South American genotype I in Brazil. J Med Virol 82: 175-185.
21. Vasconcelos PF, Costa ZG, Travassos Da Rosa ES, Luna E, Rodrigues SG, et al. (2001) Epidemic of jungle yellow fever in Brazil, 2000: implications of climatic alterations in disease spread. J Med Virol 65: 598-604.
22. Martins RM, Maia MLS, Santos EM, Cruz RLS, Santos PRG, et al. (2010) Yellow fever vaccine post-marketing surveillance in Brazil. Procedia in Vaccinology 2: 178-183.
23. Centers for Disease Control and Prevention (2010) Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mort Weekly Rep 59 (No. RR-7) (): 1-27.
24. Kuno G, Gomez I, Gubler DJ, (1987) Detecting artificial anti-dengue IgM immune complexes using an enzyme-linked immunosorbent assay. Am J Trop Med Hyg 36: 153-159.
25. De Brito T, Siqueira SA, Santos RT, Nassar ES, Coimbra TL, et al. (1992) Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. Pathol Res Pract 188: 177-181.
26. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, et al. (1998) The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 51: 506-511.
27. Vasconcelos PF, Bryant JE, da Rosa TP, Tesh RB, Rodrigues SG, et al. (2004) Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis 10: 1578-1584.
28. Beaty B, Calisher C, Shope R (1989) Arboviruses. In: Schmidt N, Emmons R, editors. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 6th edition. Washington, D. C.: American Public Health Association. pp. 797-855.
29. Galler R, Pugachev KV, Santos CL, Ocran SW, Jabor AV, et al. (2001) Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290: 309-319.
30. Vasconcelos PF, Sperb AF, Monteiro HA, Torres MA, Sousa MR, et al. (2003) Isolations of yellow fever virus from Haemagogus leucocelaenus in Rio Grande do Sul State, Brazil. Trans R Soc Trop Med Hyg 97: 60-62.
31. Brazilian Ministry of Health (2006) Guia de Vigilância Epidemiológica, 5th edition. Brasilia: Ministry of Health,.
32. Carmo EH, Penna GO, Oliveira WK, (2008) Emergências de saúde pública: conceito, caracterização, preparação e resposta. Estudos Avançados 22: 19-32.
33. Bentlin MR, Almeida RAMB, Coelho KIR, Ribeiro AF, Siciliano MM, et al. (2011) Perinatal transmission of yellow fever, Brazil, 2009. Emerg Infect Dis 17: 1779-1780.
34. Centers for Disease Control and Prevention (2010) Transmission of yellow fever vaccine virus through breast-feeding- Brazil, 2009. MMWR Morb Mortal Wkly Rep 59: 130-132.
35. Traiber C, Coelho-Amaral P, Ritter V, Winge A, (2011) Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J) 87: 269-272.
36. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, et al. (2001) Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358: 91-97.
37. Whittembury A, Ramirez G, Hernandez H, Ropero AM, Waterman S, et al. (2009) Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27: 5974-5981.
38. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, et al. (2005) Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23: 3256-3263.
39. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, et al. (2008) Adverse event reports following yellow fever vaccination. Vaccine 26: 6077-6082.
40. Veras MA, Flannery B, de Moraes JC, da Silva Teixeira AM, Luna EJ, et al. (2010) Yellow fever vaccination coverage among children in Brazilian capitals. Vaccine 28: 6478-6482.
41. Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, et al. (2010) Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28: 3827-3840.